ABBOTT LABORATORIES (ABT) Factsheet
Earnings-call transcript: none · IR deck: none — watch a real agent read these end-to-end →
ABBOTT LABORATORIES (ABT) Stock Analysis
Analysis from 10-Q filed 2026-07-28. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 7.3%. FCF margin 16.8%. D/E 0.6x. Source: 10-Q filed 2026-07-28.
| Metric | Value | Context |
|---|---|---|
| ROIC | 7.3% | Below expectations |
| FCF Margin | 16.8% | Strong cash generation |
| Debt/Equity | 0.6x | Moderate leverage |
ROIC 7.3% — Top 50% of sector peers. FCF margin 16.8% — Top 25%.
Explore ABBOTT LABORATORIES: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ABT: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: ABBOTT LABORATORIES earns 7.3% ROIC, Top 50% in Healthcare
ROIC TTM 7.3%, sector median -7.4%, Top 50%. DuPont: NOPAT margin 11.4% × asset turnover 0.5x. Gross margin 56.6%. Operating margin 15.8%. Source: 10-Q filed 2026-07-28.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.3% | Warning | Above sector median of -7.4% |
| Return on Equity (ROE) | 10.5% | Adequate | Moderate equity returns |
| Gross Margin | 56.6% | Excellent | Strong pricing power |
| Operating Margin | 15.8% | Good | Efficient operations |
Cash Flow: ABBOTT LABORATORIES generates $7.8B FCF at 16.8% margin, positive NaN/8 quarters
FCF TTM $7.8B. FCF margin 16.8%, Top 25%. OCF/Net income 1.8x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-07-28.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 16.8% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $7.8B | Good | Positive cash generation |
| OCF/Net Income | 1.8x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: ABBOTT LABORATORIES at 0.6x leverage, 9.6x interest coverage
Debt/Equity 0.6x. Total debt $32.6B, cash & investments $5.6B. Interest coverage 9.6x. Source: 10-Q filed 2026-07-28.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.6x | Good | Moderate leverage |
| Net Cash Position | $-27.0B | Warning | Net debt position |
| Interest Coverage | 9.6x | Good | Comfortable debt service |
Valuation: ABBOTT LABORATORIES trades at 31.9x earnings
P/E 31.9x. EV/Sales 4.3x. FCF yield 4.6%. Dividend yield 2.5%. Source: 10-Q filed 2026-07-28.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| P/E Ratio | 31.9x | Adequate | Premium valuation |
| EV/Sales | 4.3x | Good | Growth premium priced in |
| FCF Yield | 4.6% | Good | Lower cash yield |
| Dividend Yield | 2.5% | Adequate | Growth focus over income |
Capital Allocation: ABBOTT LABORATORIES returns 3.6% shareholder yield, reducing shares 0.6% YoY
Total shareholder yield 3.6% (div 2.5% + buyback 1.1%). Share count -0.6% YoY. Capital returned $6.2B TTM. Source: 10-Q filed 2026-07-28.
| Metric | ABT | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.6% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.1% | Adequate | Minimal buyback activity |
| Share Count Change (YoY) | -0.6% | Adequate | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $6.2B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.3% | Top 50% | - |
| Free Cash Flow Margin | 16.8% | Top 25% | 25.7x above |
| Gross Margin | 56.6% | Bottom 50% | 0.9x below |
| Operating Margin | 15.8% | Top 25% | - |
| Return on Equity (ROE) | 10.5% | Top 50% | - |
| P/E Ratio | 31.9x | N/A | - |
Financial Scorecard
| Metric | ABT | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 7.3% | Warning | Top 50% of sector (median: -7.4%) |
| Free Cash Flow Margin | 16.8% | Good | Top 25% of sector (median: 0.7%) |
| Gross Margin | 56.6% | Excellent | Bottom 50% of sector (median: 63.7%) |
| Debt to Equity Ratio | 63.8% | Good | Moderate leverage |
| P/E Ratio (Price-to-Earnings) | 31.9x | Adequate | Growth premium |
| Free Cash Flow Yield | 4.6% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is ABBOTT LABORATORIES's Return on Invested Capital (ROIC)?
ABBOTT LABORATORIES (ABT) has a trailing twelve-month Return on Invested Capital (ROIC) of 7.3%. The 8-quarter median ROIC is 10.1% with a declining trend. Sector median -7.4%. Source: 10-Q filed 2026-07-28.
Q: What is ABBOTT LABORATORIES's Free Cash Flow Margin?
ABBOTT LABORATORIES (ABT) has a free cash flow margin of 16.8%, generating $7.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-07-28.
Q: What is ABBOTT LABORATORIES's P/E ratio and how does it compare to peers?
ABBOTT LABORATORIES (ABT) trades at a P/E ratio of 31.9x, which is above the sector median of N/A. EV/Sales 4.3x. FCF yield 4.6%. Source: 10-Q filed 2026-07-28.
Q: Does ABBOTT LABORATORIES pay a dividend?
ABBOTT LABORATORIES (ABT) currently pays a dividend yield of 2.5%. Total shareholder yield (dividend + buybacks) 3.6%. Source: 10-Q filed 2026-07-28.
Q: How much debt does ABBOTT LABORATORIES have?
ABBOTT LABORATORIES (ABT) has a debt-to-equity ratio of 0.6x with total debt of $32.6 billion. Interest coverage 9.6x. Net debt $27.0 billion. Source: 10-Q filed 2026-07-28.
Q: What is ABBOTT LABORATORIES's revenue and earnings growth?
ABBOTT LABORATORIES (ABT) grew revenue by 8.1% year-over-year. EPS -61.1% YoY. Source: 10-Q filed 2026-07-28.
Q: Is ABBOTT LABORATORIES buying back stock?
ABBOTT LABORATORIES (ABT) repurchased $1.8 billion of stock over the trailing twelve months. This represents a buyback yield of 1.1%. Share count -0.6% YoY. Source: 10-Q filed 2026-07-28.
Q: How does ABBOTT LABORATORIES compare to competitors in Healthcare?
Compared to other companies in Healthcare, ABBOTT LABORATORIES (ABT) shows: ROIC 7.3%, sector median -7.4% (Top 50%). FCF margin 16.8%, sector median 0.7% (Top 25%). Gross margin 56.6%, 7.1pp below sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with ABBOTT LABORATORIES?
Quantitative warning flags for ABBOTT LABORATORIES (ABT): 1) ROIC declining -8.1% over 8 quarters. Source: 10-Q filed 2026-07-28.
Data Source: Data sourced from 10-Q filed 2026-07-28. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.